<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
Image © REDPIXEL - stock.adobe.com.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South East, interviews Alastair Smith, Chief Executive Officer at Avacta Group. The AIM-listed company, which recently raised £11.6 million, has developed Affimer® technology, an alternative to antibodies, for use in research, diagnostics, and therapeutics. In this interview, Alastair Smith provides an operational update and outlines Avacta's plans for future development.

This interview was filmed and produced by the financial website group London South East, www.lse.co.uk.

Learn more: In July 2018, Avacta's CEO spoke to LSX about Affimer® technology's market potential, licensing and partnering opportunities, and the company’s strategic objectives. Read the interview here

 

Feature image © REDPIXEL – stock.adobe.com

LSX
Written By

Add Your Response